Skip to main content
universidade lusófona

Nuno Ricardo De Almeida Saraiva

Nuno Saraiva is an Assistant Professor at Universidade Lusófona and a Principal Investigator at CBIOS, with a background in molecular biology and cell biology; he holds a PhD from Imperial College London (2012), following earlier training at the University of Lisbon and postdoctoral research at the University of Cambridge.

 His teaching and research focus on molecular and cellular mechanisms of cancer progression, particularly organelle signalling, Golgi Ca2+ homeostasis, redox regulation, cell migration and invasion. His current research investigates how dysregulated secretory pathway ion channels, especially TMBIM proteins, influence cancer cell fate and invasive behaviour, with growing emphasis on glioma biology and translational opportunities.

According to Scopus, he has authored 47 publications and has an h-index of 20, with peer-reviewed work published in journals including Journal of Cell BiologyJournal of Biological Chemistry and Redox Biology. He has led or participated in funded research, mobility and training projects supported by FCT, COST, Erasmus and institutional programmes. He has supervised more than 20 undergraduate/research initiation students, 16 MSc projects and one PhD student, and currently supervises 2 PhD and 4 MSc candidates.

His scientific career includes international research experience and collaborations with institutions such as the University of Cambridge, King’s College London, the University of Vienna, the University of Rouen and the Federal University of Pelotas. At CBIOS, he co-directs the Models & Molecular Mechanisms Lab and has established shared flow cytometry and fluorescence microscopy capabilities.

His international recognition includes service as evaluator for Marie Skłodowska-Curie Postdoctoral Fellowships, management committee membership in COST Actions including EuroCellNet and ERNEST, and participation in Net4Brain. He serves on the Editorial Board of Biology, and acts as Review Editor for Frontiers in Pharmacology and Frontiers in Oncology.